David C. Lathbury, Ph.D. has been appointed vice president of chemical development at AMRI. Dr. Lathbury will assume leadership for AMRI’s chemical development business, including operations in Albany, Rensselaer and Syracuse, NY. He will be responsible for the coordination of global projects spanning all chemical development operations, including the company’s sites in Wales, UK and Hyderabad, India, to further optimize operations and technology transfer activities. He reports to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing.

Dr. Lathbury has more than 23 years of industrial and leadership experience in process development and optimization, scale up and technical transfer of products in the pharmaceutical and agrochemical industry. Most recently, he served as director of process chemistry for AstraZeneca Process Research and Development (PR&D), where he was actively involved in setting global PR&D strategy for AZ’s Discovery/PR&D interface and outsourcing functions. He also spent seven years at Smithkline Beecham Pharmaceutical’s Synthetic Chemistry division serving in roles of increasing responsibility focused on process development and technology transfer. He also held leadership roles at MTM Fine Chemicals and Shell Research.


Click here to learn more about AMRI.